Last update 01 Nov 2024

Ube Industries Central Hospital Corp.

Subsidiary Company|

Osaka-fu, Japan

Subsidiary Company|

Osaka-fu, Japan

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Ube Industries Central Hospital Corp.

JPRN-UMIN000053727 / Completed

Association of peripheral nerve block under general anesthesia on postoperative nausea and vomiting: a nationwide population-based study - Association of peripheral nerve block under general anesthesia on postoperative nausea and vomiting: a nationwide population-based study

Start Date28 Feb 2024

Sponsor / Collaborator

Ube Industries Central Hospital Corp.

JPRN-UMIN000039346 / Recruiting

The incidence of phrenic nerve palsy after Clavipectoral fascial plane block - The incidence of phrenic nerve palsy after Clavipectoral fascial plane block

Start Date01 Jan 2020

Sponsor / Collaborator

Ube Industries Central Hospital Corp.

JPRN-UMIN000037866 / Completed

Examination of fascia illiac block area using thermography - Examination of fascia illiac block area using thermography

Start Date31 Aug 2019

Sponsor / Collaborator

Ube Industries Central Hospital Corp.

100 Clinical Results associated with Ube Industries Central Hospital Corp.

0 Patents (Medical) associated with Ube Industries Central Hospital Corp.

104

Literatures (Medical) associated with Ube Industries Central Hospital Corp.

01 Sep 2024·Journal of Clinical Anesthesia

Development and validation of a machine learning model to predict postoperative delirium using a nationwide database: A retrospective, observational study

Article

Author: Koga, Mami ; Shiramoto, Hiroko ; Morimoto, Yasuhiro ; Yoshimura, Manabu

STUDY OBJECTIVEPostoperative delirium is a neuropsychological syndrome that typically occurs in surgical patients. Its onset can lead to prolonged hospitalization as well as increased morbidity and mortality. Therefore, it is important to promptly identify its signs. This study aimed to develop and validate a machine learning predictive model for postoperative delirium using extensive population data.DESIGNRetrospective observational study.SETTINGJapanese Diagnosis Procedure Combination inpatient data. Data were used for internal (2016.4-2018.12) and temporal validation (2019.01-2019.10).PATIENTSPatients aged ≥65 years who underwent general anesthesia for surgical procedure.MEASUREMENTSThe primary outcome was postoperative delirium, which was defined as a condition requiring newly prescribed antipsychotic drugs or assignment of the corresponding insurance claim code after the date of surgery. We trained and tuned the optimal machine-learning model through 10-fold cross-validation using the selected optimal area under the receiver operating characteristic curve (AUC) value. In the temporal validation, we measured the performance of our model.MAIN RESULTSThe analysis included 557,990 patients. The light-gradient boosting machine models showed a higher AUC value (0.826 [95% confidence interval (CI): 0.822-0.829]) than the other models. Regarding performance, the model had a recall value of 0.124 (95% CI: 0.119-0.129) and precision value of 0.659 (95% CI: 0.641-0.677]). This performance was sustained in the temporal validation (AUC, 0.815 [95% CI: 0.811-0.818]). At a sensitivity of 0.80, the model achieved a specificity of 0.672 (95% CI: 0.670-0.674]), a negative predictive value of 0.975 (95% CI: 0.974-0.975), and a positive predictive value of 0.176 (95% CI: 0.176-0.179).CONCLUSIONSUsing extensive Diagnostic Procedure Combination data, we successfully created and validated a machine learning model for predicting postoperative delirium. This model may facilitate prediction of postoperative delirium.

01 Jul 2024·Pancreas

Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001)

Article

Author: Tokumitsu, Yukio ; Nishimura, Taku ; Hamano, Kimikazu ; Tanaka, Hidekazu ; Yahara, Noboru ; Ioka, Tatsuya ; Takami, Taro ; Nagano, Hiroaki ; Inokuchi, Toshihiro ; Matsui, Hiroto ; Harada, Eijiro ; Takahashi, Tsuyoshi ; Ito, Katsuyoshi ; Maeda, Yoshinari ; Kubo, Hidefumi ; Nakajima, Masao ; Shindo, Yoshitaro ; Kawaoka, Toru

ObjectivesThe present multicenter prospective observational study investigated the effectiveness and safety of neoadjuvant chemotherapy (NAC) for patients with borderline resectable pancreatic cancer (BRPC) and those with RPC contacting major vessels, with respect to a historical control of upfront surgery.Materials and MethodsPatients with BRPC and RPC contacting major vessels were prospectively registered and administered NAC with durations and regimens determined by the corresponding treating physician. Our primary aim was to assess the R0 resection rate, and secondary aim was to evaluate safety, resection rate, time to treatment failure, overall survival, and response rate.ResultsFifty of 52 enrolled patients were analyzed; 2 with serious comorbidities died during treatment. Thirty-one patients underwent resection, with R0 resection being achieved in 26 (52% of total and 84% of all resected cases). Univariate and multivariate analyses indicated age (≥75 years) as the only independent predictor of nonresection. Median progression-free survival and median survival time were longer in the prospective cohort than in the historical cohort.ConclusionsOverall, NAC for BRPC in real-world setting might yield R0 resection rates similar to those reported in previous clinical studies. Development of safe regimens and management strategies that can maintain treatment intensity in geriatric patients is warranted.

01 Dec 2023·Journal of Cardiothoracic and Vascular Anesthesia

Association Between the Use of Midazolam During Cardiac Anesthesia and the Incidence of Postoperative Delirium: A Retrospective Cohort Study Using a Nationwide Database

Article

Author: Hidaka, Yoshiyuki ; Morimoto, Yasuhiro ; Yoshimura, Manabu

OBJECTIVETo evaluate the association between the intraoperative administration of midazolam and the incidence of postoperative delirium in patients undergoing cardiac surgery.DESIGNRetrospective observational cohort study.SETTINGThe Japanese Diagnosis Procedure Combination database.PARTICIPANTSPatients aged 65 years and older who underwent cardiovascular surgery (excluding transcatheter surgeries, multiple surgeries per admission, and preoperative delirium) between April 1, 2015, and October 31, 2019.MEASUREMENTS AND MAIN RESULTSPatients who received midazolam (midazolam group) were compared with those who did not receive midazolam (no midazolam group). The primary outcome was the incidence of postoperative delirium. The secondary outcomes were the incidence of postoperative nausea and vomiting, mortality, and duration of intensive care unit stay and hospitalization. Propensity scores were estimated using logistic regression based on the covariates. The outcomes were compared using stabilized inverse probability of treatment-weighting analyses. Among the 16,185 patients analyzed, 10,633 (65.7%) received midazolam. No significant differences were observed in the incidences of postoperative delirium (odds ratio [OR] 0.95; 95% CI 0.87-1.03; p = 0.21) and hospital mortality (OR 0.92; 95% CI 0.76-1.11; p = 0.39) between the groups; however, the midazolam group had slightly longer durations of intensive care unit stay (3.5 [3.5-3.6] v 3.3 [3.3-3.4] days, p < 0.001) and hospitalization (31.5 [31.1-31.9] v 29.4 [28.8-29.9] days, p < 0.001), and slightly lower incidences of postoperative nausea and vomiting (OR 0.92; 95% CI 0.85-0.99; p = 0.03). The sensitivity analyses supported these results.CONCLUSIONSIntraoperative administration of midazolam may not induce postoperative delirium in patients undergoing cardiac surgery.

100 Deals associated with Ube Industries Central Hospital Corp.

100 Translational Medicine associated with Ube Industries Central Hospital Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ube Industries Central Hospital Corp.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing